EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts

  • ID: 3292819
  • Report
  • October 2016
  • Region: Global
  • 191 Pages
  • CurrentPartnering
1 of 4
The Global Cancer Vaccine Partnering 2010-2016 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value

The Global Cancer Vaccine Partnering 2010-2016 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 150 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

This report provides details of the latest cancer vaccine agreements announced in the healthcare sectors covering the following diagnostics types including adjuvant.

Attenuated vaccine
Subunit vaccine
Toxoid vaccine
Conjugate vaccine
Inactivated vaccine
DNA vaccine
Recombinant vector vaccine

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive cancer vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering cancer vaccine partnering deals.

The report presents average financial deal terms values for cancer vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the cancer vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see wh- is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 150 online deals records of actual cancer vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Report scope

Global Cancer Vaccine Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

Global Cancer Vaccine Partnering 2010-2015 includes:

Trends in cancer vaccine dealmaking in the biopharma industry since 2010
Analysis of cancer vaccine deal structure
Access to headline, upfront, milestone and royalty data
Access to over 150 cancer vaccine deal records
The leading cancer vaccine deals by value since 2010
In Global Cancer Vaccine Partnering 2010-2015 , the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Vaccine Partnering 2010-2015 report provides comprehensive access to available deals and contract documents for over 160 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Vaccine dealmaking

2.1. Introduction
2.2. Cancer Vaccine partnering over the years
2.3. Most active Cancer Vaccine dealmakers
2.4. Cancer Vaccine partnering by deal type
2.5. Cancer Vaccine partnering by therapy area
2.6. Deal terms for Cancer Vaccine partnering
2.6.1 Cancer Vaccine partnering headline values
2.6.2 Cancer Vaccine deal upfront payments7
2.6.3 Cancer Vaccine deal milestone payments
2.6.4 Cancer Vaccine royalty rates

Chapter 3 - Leading Cancer Vaccine deals

3.1. Introduction
3.2. Top Cancer Vaccine deals by value

Chapter 4 - Most active Cancer Vaccine dealmakers

4.1. Introduction
4.2. Most active Cancer Vaccine dealmakers
4.3. Most active Cancer Vaccine partnering company profiles

Chapter 5 - Cancer Vaccine contracts dealmaking directory

5.1. Introduction
5.2. Cancer Vaccine contracts dealmaking directory

Chapter 6 - Cancer Vaccine dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Cancer Vaccine deals by company A-Z

Appendix 2 - Cancer Vaccine deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Cancer Vaccine deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 - Cancer Vaccine deals by therapy area

Appendix 5 -Deal type definitions

About

Table of figures

Figure 1: Cancer Vaccine partnering since 2010
Figure 2: Active Cancer Vaccine dealmaking activity- 2010 to 2016
Figure 3: Cancer Vaccine partnering by deal type since 2010
Figure 4: Cancer Vaccine partnering by disease type since 2010
Figure 5: Cancer Vaccine deals with a headline value
Figure 6: Cancer Vaccine deals with an upfront value
Figure 7: Cancer Vaccine deals with a milestone value
Figure 8: Cancer Vaccine deals with a royalty rate value
Figure 9: Top Cancer Vaccine deals by value since 2010
Figure 10: Most active Cancer Vaccine dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
Note: Product cover images may vary from those shown
3 of 4
Global Cancer Vaccine Partnering 2010-2016 report provides the reader with the following key benefits:

- In-depth understanding of Cancer Vaccine deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Cancer Vaccine agreements with numerous real life case studies
- Detailed access to actual Cancer Vaccine contracts entered into by leading biopharma companies
- Identify most active Cancer Vaccine dealmakers since 2010
- Insight into terms included in a Cancer Vaccine partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll